In this interview, Pablo Mora discusses phase 2b findings for zenagamtide (amycretin), a novel unimolecular GLP-1 and amylin receptor agonist, including its effects on glycemic control and body weight in people with type 2 diabetes, and the potential of ongoing phase 3 trials.
In this interview at EASD 2026, Katherine Tuttle discusses ACHIEVE-4 findings on the potential kidney-protective effects of orforglipron in people with type 2 diabetes and high cardiovascular risk, and the need for dedicated trials to confirm its long-term renal benefits.
New findings presented at EASD 2026 suggest that mild, lifelong reductions in insulin signaling may be associated with a more favorable metabolic profile, challenging the view that all forms of insulin resistance are detrimental to health.
EASD President Francesco Giorgino previews EASD 2026, discussing the key developments set to shape diabetes research and care, including incretin therapies, type 1 diabetes, AI and diabetes technology, personalized care, screening, and his priorities for EASD during his presidency.
In this EASD 2026 interview, Viral Shah discusses how continuous glucose monitoring could support earlier diabetes diagnosis, improve risk prediction and enable more personalized treatment and monitoring.
In this interview at EASD 2026, Professor Kirsi Pietiläinen discusses SYNCHRONIZE-1 findings on survodutide, its effects on body composition and liver fat, and the potential of dual glucagon and GLP-1 receptor agonism in obesity and MASLD.
